Sports Research and Anti-Doping: The Canadian Context
Evidence level: This article summarizes publicly available regulatory frameworks — the WADA Prohibited List, Canada’s Anti-Doping Program and Health Canada’s drug classification framework — rather than reporting new research. It is general information, not legal advice. The rules around Canadian anti-doping peptides regulations are often misunderstood by athletes and researchers alike.
Anyone following peptide and research-compound science in Canada will eventually run into two separate regulatory systems that get discussed together but actually answer different questions: sport anti-doping rules, which govern what competitive athletes can have in their system, and Health Canada’s drug framework, which governs what can be marketed and sold as a drug in Canada. This article summarizes both in plain language.
Who Canada’s anti-doping rules actually apply to
Sport Integrity Canada (formerly the Canadian Centre for Ethics in Sport) administers the Canadian Anti-Doping Program (CADP), described as designed “to prevent, deter and detect doping and serve to protect the integrity of sport and the rights of clean athletes.” The CADP applies to athletes, support personnel and others affiliated with sport organizations that have formally adopted it — currently more than 70 national and multi-sport organizations — and is maintained in alignment with the World Anti-Doping Code and its International Standards. Read about the Canadian Anti-Doping Program.
In other words, the CADP is not a general Canadian law that applies to everyone — it is a sport-governance framework that binds people affiliated with the organizations that have adopted it.
Canadian Anti-Doping Peptides: What Does WADA Actually Prohibit?
The WADA Prohibited List — which the CADP follows — organizes substances and methods into categories. Several categories are prohibited at all times, both in and out of competition, including non-approved substances (S0), anabolic agents (S1), and peptide hormones, growth factors and related substances (S2), a category that includes compounds such as erythropoietin (EPO), chorionic gonadotrophin, luteinizing hormone and growth hormone. Other categories, such as stimulants and narcotics, are prohibited only in-competition. Read the banned substances and methods overview.
“Non-approved” is its own explicit category
Separately from S2, category S0 covers substances that lack approval by any government health authority for human therapeutic use. Sport Integrity Canada has specifically flagged research peptides such as BPC-157 as falling under this category, warning that for anyone subject to the CADP, “the use, administration, trafficking or possession of these substances could result in an anti-doping rule violation.” Read the advisory on non-approved peptides.
The list is actively updated
WADA publishes an updated Prohibited List annually. The 2026 version, effective January 1, 2026, was described by Sport Integrity Canada as containing mostly clarifications rather than major substantive changes — but those clarifications specifically included new examples added “for anabolic agents, peptide hormones, growth factors, related substances, and mimetics.” Read the 2026 update summary. Peptide-related substances remain an active area of regulatory attention rather than a settled, static list.
A separate question: what Health Canada regulates as a drug
Anti-doping status is not the same question as whether a substance is regulated as a drug in Canada generally. Under the Food and Drugs Act, Health Canada classifies a product as a drug based on several factors together — not composition alone. These include how the product is represented (claims, labelling, conditions of use), its intended purpose, its composition and its format. Read Health Canada’s classification framework. This is a genuinely complex regulatory area, and this article does not attempt to resolve how it applies to any specific product or label.
Two systems, two different questions
It is worth being explicit about the distinction: the anti-doping framework asks whether a competitive athlete bound by the CADP can have a substance in their system, in or out of competition. Health Canada’s framework asks how a product can be represented, marketed and sold within Canada. These are different bodies, different questions and different audiences — a compound can be discussed in both conversations without those conversations being the same one.
Why this distinction matters for reading peptide research
It is easy to blur scientific, regulatory and sport-governance questions together when reading about a compound. This library’s article on preclinical versus human evidence covers the scientific question — what a study actually shows. This article covers a different one — how sport governance and drug regulation each treat a substance. Keeping them separate makes it much easier to read a claim accurately, rather than assuming a scientific, regulatory or sport-eligibility statement about a compound automatically implies the others.
Frequently Asked Questions
Does the Canadian Anti-Doping Program apply to everyone in Canada?
No. It applies specifically to athletes, support personnel and others affiliated with the sport organizations that have formally adopted the CADP — it is not a general law binding the public at large.
Are all peptide hormones banned in sport?
Peptide hormones, growth factors and related substances are grouped under WADA’s S2 category, which is prohibited at all times for anyone subject to the CADP. That is a sport-eligibility question, separate from whether a given compound is generally legal to buy, sell or possess.
What does “non-approved substance” (S0) mean?
It refers to substances not approved by any government health authority for human therapeutic use. Sport Integrity Canada has specifically named research peptides like BPC-157 as falling into this prohibited category for CADP-bound athletes.
Does labelling a product “for research use only” settle its regulatory status in Canada?
Not by itself. Health Canada’s drug classification considers representation, intended purpose, composition and format together. This is a complex, fact-specific area, and general labelling language does not automatically determine how a product is regulated.
Research and educational notice: This article summarizes publicly available regulatory information for scientific and educational purposes only. It is not legal advice, does not provide medical advice, diagnosis, treatment, dosing or human-use instructions, and should not be relied on as a substitute for consulting a qualified legal professional or the relevant regulatory body directly. MacDaddy Peptides products are intended for laboratory research use only and are not approved for human or veterinary use.
Return to the Science Library | Preclinical Versus Human Evidence | How to Read a Certificate of Analysis